Metabolomic profile will be assessed along with genetic information to optimize dosing.
Metabolon and the Harvard-Partners Healthcare Center for Genetics and Genomics (HPCGG) are working together to improve diagnostic tests related to warfarin dosing. The collaborators say that they will not only examine a patient’s genetics but also the metabolomic profile to determine the correct dosing regimen for this blood-thinning agent.
Patient samples for the study are being collected as part of the ongoing HPCGG trial called Creating an Optimal Warfarin Nomogram (CROWN). It is a prospective dosing study that is focusing on genetic testing to determine the optimal warfarin dose. Sample collection for the diagnostic development should be complete in the summer. Metabolon will then conduct the metabolomic analysis.
HPCGG investigators also have received preferred access to Metabolon’s global biochemical profiling platform. These services provide for the extraction, identification, and quantitation of small molecules. The platform also highlights significantly altered metabolites related to these biochemicals.
